08:00 , Feb 29, 2016 |  BC Week In Review  |  Clinical News

BPZE1: Completed Phase Ib enrollment

ILiAD said INSERM completed enrollment of healthy volunteers in a single-blind, placebo-controlled, dose-escalation, Swedish Phase Ib trial of single doses of intranasal BPZE1. ILiAD in-licensed the vaccine from INSERM and Institut Pasteur (see BioCentury, Jan....
08:00 , Jan 27, 2014 |  BC Week In Review  |  Company News

ILiAD Biotechnologies, Institut National de la Sante et de la Recherche Medicale, Institut Pasteur, National University of Ireland, National University of Singa

ILiAD, INSERM's Inserm Transfert S.A. subsidiary and Institut Pasteur partnered to optimize and develop live attenuated Bordetella pertussis vaccine technology, including the BPZE1 vaccine. A Phase I trial in healthy adults showed that BPZE1...